tetano
Editor, Senior Moderator
BMC Infect Dis
. 2024 Nov 8;24(1):1266.
doi: 10.1186/s12879-024-10124-6. Genomic characteristics, disease outcome and heterologous vaccine effectiveness among cases with SARS CoV-2 infection
Rowan Abuyadek[SUP] #[/SUP][SUP] 1 2 [/SUP], Mira Mousa[SUP] #[/SUP][SUP] 3 4 [/SUP], Jumana AlAzazi[SUP] 5 [/SUP], Ahmed Al Romaithi[SUP] 6 [/SUP], Francis Selvaraj[SUP] 7 [/SUP], Habiba Alsafar[SUP] 3 8 [/SUP], Nawal Al Kaabi[SUP] 9 10 [/SUP], Farida Al Hosani[SUP] 1 [/SUP]
Affiliations
Background: In the pursuit of global health security, continuous monitoring of vaccine effectiveness across various viral strains emerges as a crucial imperative. The emergence of SARS-CoV-2 major variants of concern (VOCs), including Alpha, Beta, Delta, and Omicron, has added complexity to the COVID-19 vaccination landscape.
Objectives: To assess illness severity, evaluate vaccine efficacy across varying doses and types, and determine effectiveness against major VOCs within the population.
Methods: This retrospective cohort study, conducted in Abu Dhabi, United Arab Emirates, focuses on a cohort of 44,073 SARS-CoV-2 positive cases from February 2021 to May 2022, dominated by the Delta and Omicron variants. The study employed a nested case-control design, analyzing hospital admissions for confirmed SARS-CoV-2 infection.
Results: Vaccine effectiveness was higher among heterologus-boosted individuals at 87% (95% CI:79%-93%) compared to homologus-boosted individuals at 59% (95% CI: 48%-68%) and fully vaccinated, non-boosted adults at 53% (95% CI: 46%-59%). These findings highlight the importance of heterologous boosting, particularly against rapidly evolving viral variants, offering valuable insights for refining pandemic response strategies.
Conclusion: The study underscores the critical need for ongoing assessment and adaptation of vaccination strategies to the evolving viral landscape.
Keywords: Booster; Heterologous; Homologous; Pandemic; SARS CoV-2; Severity; Vaccine; Variant of concern; virus.
. 2024 Nov 8;24(1):1266.
doi: 10.1186/s12879-024-10124-6. Genomic characteristics, disease outcome and heterologous vaccine effectiveness among cases with SARS CoV-2 infection
Rowan Abuyadek[SUP] #[/SUP][SUP] 1 2 [/SUP], Mira Mousa[SUP] #[/SUP][SUP] 3 4 [/SUP], Jumana AlAzazi[SUP] 5 [/SUP], Ahmed Al Romaithi[SUP] 6 [/SUP], Francis Selvaraj[SUP] 7 [/SUP], Habiba Alsafar[SUP] 3 8 [/SUP], Nawal Al Kaabi[SUP] 9 10 [/SUP], Farida Al Hosani[SUP] 1 [/SUP]
Affiliations
- PMID: 39516737
- DOI: 10.1186/s12879-024-10124-6
Background: In the pursuit of global health security, continuous monitoring of vaccine effectiveness across various viral strains emerges as a crucial imperative. The emergence of SARS-CoV-2 major variants of concern (VOCs), including Alpha, Beta, Delta, and Omicron, has added complexity to the COVID-19 vaccination landscape.
Objectives: To assess illness severity, evaluate vaccine efficacy across varying doses and types, and determine effectiveness against major VOCs within the population.
Methods: This retrospective cohort study, conducted in Abu Dhabi, United Arab Emirates, focuses on a cohort of 44,073 SARS-CoV-2 positive cases from February 2021 to May 2022, dominated by the Delta and Omicron variants. The study employed a nested case-control design, analyzing hospital admissions for confirmed SARS-CoV-2 infection.
Results: Vaccine effectiveness was higher among heterologus-boosted individuals at 87% (95% CI:79%-93%) compared to homologus-boosted individuals at 59% (95% CI: 48%-68%) and fully vaccinated, non-boosted adults at 53% (95% CI: 46%-59%). These findings highlight the importance of heterologous boosting, particularly against rapidly evolving viral variants, offering valuable insights for refining pandemic response strategies.
Conclusion: The study underscores the critical need for ongoing assessment and adaptation of vaccination strategies to the evolving viral landscape.
Keywords: Booster; Heterologous; Homologous; Pandemic; SARS CoV-2; Severity; Vaccine; Variant of concern; virus.